Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score

Objective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis. Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angiop...

Full description

Saved in:
Bibliographic Details
Main Authors: Elena Myasoedova, Bharath Manu Akkara Veetil, Eric L. Matteson, Hilal Maradit Kremers, Marian T. McEvoy, Cynthia S. Crowson
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Scientifica
Online Access:http://dx.doi.org/10.1155/2013/371569
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850220348926066688
author Elena Myasoedova
Bharath Manu Akkara Veetil
Eric L. Matteson
Hilal Maradit Kremers
Marian T. McEvoy
Cynthia S. Crowson
author_facet Elena Myasoedova
Bharath Manu Akkara Veetil
Eric L. Matteson
Hilal Maradit Kremers
Marian T. McEvoy
Cynthia S. Crowson
author_sort Elena Myasoedova
collection DOAJ
description Objective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis. Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting using the FRS, to the observed risk of cardiovascular events in a population-based cohort of patients with psoriasis. Patients with incident or prevalent adult-onset psoriasis aged 30–79 years without prior history of cardiovascular disease were included. Results. Among the 1197 patients with predicted risk scores, the median FRS was 6.0%, while the observed 10-year cardiovascular risk was 6.9% (standardized incidence ratio (SIR): 1.14; 95% confidence interval (CI): 0.92–1.42). The SIR was not elevated for women nor for men. The differences between observed and predicted cardiovascular risks in patients <60 years (SIR: 1.01; 95% CI: 0.73–1.41) or ≥60 years (SIR: 1.26; 95% CI: 0.95–1.68) were not statistically significant. Conclusion. There was no apparent difference between observed and predicted cardiovascular risks in patients with psoriasis in our study. FRS reasonably estimated cardiovascular risk in both men and women as well as in younger and older psoriasis patients, suggesting that FRS can be used in risk stratification in psoriasis without further adjustment.
format Article
id doaj-art-77b3e09442954e94a004bcd88c0e8fea
institution OA Journals
issn 2090-908X
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Scientifica
spelling doaj-art-77b3e09442954e94a004bcd88c0e8fea2025-08-20T02:07:06ZengWileyScientifica2090-908X2013-01-01201310.1155/2013/371569371569Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk ScoreElena Myasoedova0Bharath Manu Akkara Veetil1Eric L. Matteson2Hilal Maradit Kremers3Marian T. McEvoy4Cynthia S. Crowson5Division of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USADivision of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USADivision of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USADepartment of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USADepartment of Dermatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USADivision of Rheumatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USAObjective. To examine the utility of the Framingham risk score (FRS) in estimating cardiovascular risk in psoriasis. Methods. We compared the predicted 10-year risk of cardiovascular events, namely, cardiovascular death, myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting using the FRS, to the observed risk of cardiovascular events in a population-based cohort of patients with psoriasis. Patients with incident or prevalent adult-onset psoriasis aged 30–79 years without prior history of cardiovascular disease were included. Results. Among the 1197 patients with predicted risk scores, the median FRS was 6.0%, while the observed 10-year cardiovascular risk was 6.9% (standardized incidence ratio (SIR): 1.14; 95% confidence interval (CI): 0.92–1.42). The SIR was not elevated for women nor for men. The differences between observed and predicted cardiovascular risks in patients <60 years (SIR: 1.01; 95% CI: 0.73–1.41) or ≥60 years (SIR: 1.26; 95% CI: 0.95–1.68) were not statistically significant. Conclusion. There was no apparent difference between observed and predicted cardiovascular risks in patients with psoriasis in our study. FRS reasonably estimated cardiovascular risk in both men and women as well as in younger and older psoriasis patients, suggesting that FRS can be used in risk stratification in psoriasis without further adjustment.http://dx.doi.org/10.1155/2013/371569
spellingShingle Elena Myasoedova
Bharath Manu Akkara Veetil
Eric L. Matteson
Hilal Maradit Kremers
Marian T. McEvoy
Cynthia S. Crowson
Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
Scientifica
title Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
title_full Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
title_fullStr Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
title_full_unstemmed Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
title_short Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
title_sort cardiovascular risk in psoriasis a population based analysis with assessment of the framingham risk score
url http://dx.doi.org/10.1155/2013/371569
work_keys_str_mv AT elenamyasoedova cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore
AT bharathmanuakkaraveetil cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore
AT ericlmatteson cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore
AT hilalmaraditkremers cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore
AT mariantmcevoy cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore
AT cynthiascrowson cardiovascularriskinpsoriasisapopulationbasedanalysiswithassessmentoftheframinghamriskscore